The GH/IGF-1 system in critical illness

Itoro E. Elijah, Ludwik Branski, Celeste Finnerty, David Herndon

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The Growth Hormone and Insulin-like Growth Factor-1 (IGF-1) axis plays a pivotal role in critical illness, with a derangement leading to profound changes in metabolism. Protein wasting with skeletal muscle loss, delayed wound healing, and impaired recovery of organ systems are some of the most feared consequences. The use of human recombinant Growth Hormone (rhGH) and Insulin-like Growth Factor-1 (IGF-1) - alone and in combination - has been studied extensively in preclinical and clinical trials. This article reviews the current knowlegde and clinical practice of the use of rhGh and IGF-1 in critically ill patients, with a special focus on the trauma and burns patient population.

Original languageEnglish (US)
Pages (from-to)759-767
Number of pages9
JournalBest Practice and Research: Clinical Endocrinology and Metabolism
Volume25
Issue number5
DOIs
StatePublished - Oct 2011

Fingerprint

Somatomedins
Critical Illness
Growth Hormone
Human Growth Hormone
Wound Healing
Skeletal Muscle
Clinical Trials
Wounds and Injuries
Population
Proteins

Keywords

  • anabolic therapy
  • burns
  • gut atrophy
  • hepatic acute care response
  • hypermetabolism
  • IGFBP-3
  • mortality
  • nutrition
  • protein wasting
  • trauma

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

The GH/IGF-1 system in critical illness. / Elijah, Itoro E.; Branski, Ludwik; Finnerty, Celeste; Herndon, David.

In: Best Practice and Research: Clinical Endocrinology and Metabolism, Vol. 25, No. 5, 10.2011, p. 759-767.

Research output: Contribution to journalArticle

@article{7ef17cc166df4e6b89a54152080ee92b,
title = "The GH/IGF-1 system in critical illness",
abstract = "The Growth Hormone and Insulin-like Growth Factor-1 (IGF-1) axis plays a pivotal role in critical illness, with a derangement leading to profound changes in metabolism. Protein wasting with skeletal muscle loss, delayed wound healing, and impaired recovery of organ systems are some of the most feared consequences. The use of human recombinant Growth Hormone (rhGH) and Insulin-like Growth Factor-1 (IGF-1) - alone and in combination - has been studied extensively in preclinical and clinical trials. This article reviews the current knowlegde and clinical practice of the use of rhGh and IGF-1 in critically ill patients, with a special focus on the trauma and burns patient population.",
keywords = "anabolic therapy, burns, gut atrophy, hepatic acute care response, hypermetabolism, IGFBP-3, mortality, nutrition, protein wasting, trauma",
author = "Elijah, {Itoro E.} and Ludwik Branski and Celeste Finnerty and David Herndon",
year = "2011",
month = "10",
doi = "10.1016/j.beem.2011.06.002",
language = "English (US)",
volume = "25",
pages = "759--767",
journal = "Best Practice and Research in Clinical Endocrinology and Metabolism",
issn = "1521-690X",
publisher = "Bailliere Tindall Ltd",
number = "5",

}

TY - JOUR

T1 - The GH/IGF-1 system in critical illness

AU - Elijah, Itoro E.

AU - Branski, Ludwik

AU - Finnerty, Celeste

AU - Herndon, David

PY - 2011/10

Y1 - 2011/10

N2 - The Growth Hormone and Insulin-like Growth Factor-1 (IGF-1) axis plays a pivotal role in critical illness, with a derangement leading to profound changes in metabolism. Protein wasting with skeletal muscle loss, delayed wound healing, and impaired recovery of organ systems are some of the most feared consequences. The use of human recombinant Growth Hormone (rhGH) and Insulin-like Growth Factor-1 (IGF-1) - alone and in combination - has been studied extensively in preclinical and clinical trials. This article reviews the current knowlegde and clinical practice of the use of rhGh and IGF-1 in critically ill patients, with a special focus on the trauma and burns patient population.

AB - The Growth Hormone and Insulin-like Growth Factor-1 (IGF-1) axis plays a pivotal role in critical illness, with a derangement leading to profound changes in metabolism. Protein wasting with skeletal muscle loss, delayed wound healing, and impaired recovery of organ systems are some of the most feared consequences. The use of human recombinant Growth Hormone (rhGH) and Insulin-like Growth Factor-1 (IGF-1) - alone and in combination - has been studied extensively in preclinical and clinical trials. This article reviews the current knowlegde and clinical practice of the use of rhGh and IGF-1 in critically ill patients, with a special focus on the trauma and burns patient population.

KW - anabolic therapy

KW - burns

KW - gut atrophy

KW - hepatic acute care response

KW - hypermetabolism

KW - IGFBP-3

KW - mortality

KW - nutrition

KW - protein wasting

KW - trauma

UR - http://www.scopus.com/inward/record.url?scp=80052932048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052932048&partnerID=8YFLogxK

U2 - 10.1016/j.beem.2011.06.002

DO - 10.1016/j.beem.2011.06.002

M3 - Article

C2 - 21925076

AN - SCOPUS:80052932048

VL - 25

SP - 759

EP - 767

JO - Best Practice and Research in Clinical Endocrinology and Metabolism

JF - Best Practice and Research in Clinical Endocrinology and Metabolism

SN - 1521-690X

IS - 5

ER -